Steven Cohen Celldex Therapeutics, Inc. Transaction History
Point72 Asset Management, L.P.
- $44.6 Billion
- Q2 2025
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 2,801,721 shares of CLDX stock, worth $68.5 Million. This represents 0.13% of its overall portfolio holdings.
Number of Shares
2,801,721
Previous 2,621,175
6.89%
Holding current value
$68.5 Million
Previous $47.6 Million
19.84%
% of portfolio
0.13%
Previous 0.12%
Shares
14 transactions
Others Institutions Holding CLDX
# of Institutions
198Shares Held
68.2MCall Options Held
219KPut Options Held
238K-
Kynam Capital Management, LP Princeton, NJ6.1MShares$149 Million14.83% of portfolio
-
Wellington Management Group LLP Boston, MA5.23MShares$128 Million0.02% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$115 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.96MShares$96.8 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.82MShares$93.3 Million0.01% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.14B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...